A detailed history of Two Sigma Investments, LP transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, Two Sigma Investments, LP holds 732,282 shares of AUTL stock, worth $2.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
732,282
Previous 1,005,916 27.2%
Holding current value
$2.2 Million
Previous $3.5 Million 24.06%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.38 - $4.69 $924,882 - $1.28 Million
-273,634 Reduced 27.2%
732,282 $2.66 Million
Q2 2024

Aug 14, 2024

BUY
$3.33 - $5.68 $2.59 Million - $4.41 Million
777,074 Added 339.57%
1,005,916 $3.5 Million
Q1 2024

May 15, 2024

SELL
$5.39 - $7.29 $153,151 - $207,138
-28,414 Reduced 11.05%
228,842 $1.46 Million
Q4 2023

Feb 14, 2024

BUY
$2.13 - $6.63 $88,524 - $275,549
41,561 Added 19.27%
257,256 $1.66 Million
Q3 2023

Nov 14, 2023

SELL
$2.32 - $3.36 $215,973 - $312,789
-93,092 Reduced 30.15%
215,695 $502,000
Q2 2023

Aug 14, 2023

BUY
$1.64 - $3.21 $353,170 - $691,267
215,348 Added 230.47%
308,787 $734,000
Q1 2023

May 15, 2023

BUY
$1.75 - $2.25 $104,543 - $134,412
59,739 Added 177.27%
93,439 $171,000
Q4 2022

Feb 14, 2023

BUY
$1.74 - $3.27 $58,638 - $110,199
33,700 New
33,700 $64,000
Q2 2021

Aug 16, 2021

SELL
$4.78 - $7.96 $368,729 - $614,034
-77,140 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$5.49 - $9.36 $423,498 - $722,030
77,140 New
77,140 $442,000
Q4 2020

Feb 16, 2021

SELL
$8.13 - $12.79 $269,729 - $424,333
-33,177 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$11.64 - $16.3 $386,180 - $540,785
33,177 New
33,177 $386,000

Others Institutions Holding AUTL

About Autolus Therapeutics plc


  • Ticker AUTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 90,909,800
  • Market Cap $274M
  • Description
  • Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...
More about AUTL
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.